HQL Stock Analysis: Tekla Life Sciences | NYSE
Asset Management | NYSE, USA | Market Cap: 650m USD | 12M Return: 80.6% | US87911K1007 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.53M
Warnings
No concerns identified
Tailwinds
Seasonality
Abrdn Life Sciences Investors (HQL) is a U.S.-domiciled closed-end equity fund launched in 1992 and managed by abrdn Inc. The fund invests globally in public equities, concentrating on the life sciences sector, including biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, medical devices and supplies, as well as agriculture and environmental management industries.
Management constructs the portfolio primarily from small-cap growth stocks, using fundamental analysis that weighs factors such as competitive market position, management experience, technological expertise, and access to capital. Performance is benchmarked against the NASDAQ Biotech Index and the S&P 500 Index. As a closed-end fund, HQL is listed on the NYSE and is classified within the GICS Financials sector (Asset Management & Custody Banks); its shares trade on an exchange like a stock, giving investors fund-like portfolio exposure along with intraday liquidity and a market price that can trade at a premium or discount to net asset value.
- Fed rate cuts boost small cap biotech valuations
- Discount to NAV narrows as biotech sentiment improves
- Distribution coverage pressured by weak life sciences portfolio returns
| Net Income: 198.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA -0.44 > 1.0 |
| NWC/Revenue: 2.18% < 20% (prev -74.74%; Δ 76.92% < -1%) |
| CFO/TA -0.00 > 3% & CFO -2.49m > Net Income 198.2m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 2.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (30.4m) vs 12m ago 11.18% < -2% |
| Gross Margin: 90.69% > 18% (prev 73.39%; Δ 17.30% > 0.5%) |
| Asset Turnover: 12.25% > 50% (prev 4.89%; Δ 7.36% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.00 (Total Current Assets 2.13m - Total Current Liabilities 825k) / Total Assets 563.2m |
| B: 0.20 (Retained Earnings 111.4m / Total Assets 563.2m) |
| C: 0.41 (EBIT TTM 198.2m / Avg Total Assets 487.3m) |
| D: 233.7 (Book Value of Equity 560.8m / Total Liabilities 2.40m) |
| Altman-Z'' = 248.8 = AAA |
As of August 23, 2026, the stock is trading at USD 22.38 with a total of 169,423 shares traded. Over the past week, the price has changed by +6.07%, over one month by +12.86%, over three months by +30.04% and over the past year by +80.56%.
Current recommended Stop Loss: 21.60 (which is 3.5% or 1.6 ATR below the current price).
Tekla Life Sciences has no consensus analysts rating.
P/E Trailing = 3.3253
P/S = 3.6447
P/B = 1.2292
Revenue TTM = 59.7m USD
EBIT TTM = 198.2m USD
EBITDA TTM = 198.2m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 649.0m USD (649.8m + (null Debt) - CCE 852k)
Interest Coverage Ratio = unknown (Ebit TTM 198.2m / Interest Expense TTM 0.0)
EV/FCF = -260.1x (Enterprise Value 649.0m / FCF TTM -2.49m)
FCF Yield = -0.38% (FCF TTM -2.49m / Enterprise Value 649.0m)
FCF Margin = -4.18% (FCF TTM -2.49m / Revenue TTM 59.7m)
Net Margin = 331.9% (Net Income TTM 198.2m / Revenue TTM 59.7m)
Gross Margin = 90.69% ((Revenue TTM 59.7m - Cost of Revenue TTM 5.56m) / Revenue TTM)
Gross Margin QoQ = 93.52% (prev 78.99%)
Tobins Q-Ratio = 1.15 (Enterprise Value 649.0m / Total Assets 563.2m)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 156.6m (EBIT 198.2m * (1 - 21.00%))
Current Ratio = 2.58 (Total Current Assets 2.13m / Total Current Liabilities 825k)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 198.2m)
Debt / FCF = unknown (Net Debt none / FCF TTM -2.49m)
Total Stockholder Equity = 482.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 40.67% (Net Income 198.2m / Total Assets 563.2m)
RoE = 41.07% (Net Income TTM 198.2m / Total Stockholder Equity 482.5m)
RoCE = 35.24% (EBIT 198.2m / Capital Employed (Total Assets 563.2m - Current Liab 825k))
RoIC = 27.88% (NOPAT 156.6m / Invested Capital 561.5m)
WACC = 8.86% (E(649.8m)/V(649.8m) * Re(8.86%) + (debt-free company))
Discount Rate = 8.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 54.36 | Cagr: 7.80%
[DCF] Fair Price = unknown (Cash Flow -2.49m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.35 | # QB: 1
Revenue Correlation: 50.66 | Revenue CAGR: 84.60% | SUE: N/A | # QB: 0